LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic funding Cantargia recently secured significant financing through a rights issue totaling approximately SEK 75 million before costs, indicating enhanced liquidity and potential for accelerated clinical development and partner-led initiatives.

Ownership changes Recent executive shifts include a new CEO appointed in 2025 and a Chief Medical Officer hired in 2025 with prior CMO transition in 2025; assess alignment for strategic partnerships and potential leverage points in clinical program discussions.

Partnership momentum Otsuka entered into an asset purchase agreement related to CAN10 in 2025, signaling external validation and potential opportunities for collaboration, co-development, or asset acquisition in autoimmune and inflammatory indications.

Clinical programs Two ongoing clinical programs targeting IL1RAP—nadunolimab in cancer (phase II) and CAN10 in autoimmune/inflammatory diseases (phase I)—present multiple collaboration angles for pharma, CRO, or translational research partnerships.

Industry engagement Active participation in notable scientific events (AACR 2025) and attendance at life sciences conferences in 2026 indicate a proactive market presence; leverage these forums for outbound outreach, thought leadership partnerships, and accelerated deal conversations.

Similar companies to Cantargia AB

Cantargia AB Tech Stack

Cantargia AB uses 8 technology products and services including iCIMS, GleSYS Internet Services, Microsoft SharePoint, and more. Explore Cantargia AB's tech stack below.

Cantargia AB's Email Address Formats

Cantargia AB uses at least 4 email formats:
Cantargia AB Email FormatsExamplePercentage
First.Last@cantargia.comJohn.Doe@cantargia.com
89%
First.MiddleLast@cantargia.comJohn.MichaelDoe@cantargia.com
8%
LastFirst@cantargia.comDoeJohn@cantargia.com
1%
First.Middle@cantargia.comJohn.Michael@cantargia.com
2%

Frequently Asked Questions

What is Cantargia AB's phone number?

Minus sign iconPlus sign icon You can contact Cantargia AB's main corporate office by phone at
+46-46-275-6****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cantargia AB's official website and social media links?

Minus sign iconPlus sign iconCantargia AB's official website is cantargia.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Cantargia AB generate?

Minus sign iconPlus sign icon As of August 2026, Cantargia AB's annual revenue is estimated to be <$1M.

What is Cantargia AB's SIC code and NAICS code?

Minus sign iconPlus sign iconCantargia AB's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cantargia AB have currently?

Minus sign iconPlus sign iconAs of August 2026, Cantargia AB has approximately 31 employees across 1 continents, including Europe. Key team members include Ceo: H. H. S., Chief Business Officer: T. B. and Chief Scientific Officer: D. L. Explore Cantargia AB's employee directory with LeadIQ.

What industry does Cantargia AB belong to?

Minus sign iconPlus sign iconCantargia AB operates in the Biotechnology Research industry.

What technology does Cantargia AB use?

Minus sign iconPlus sign iconCantargia AB's tech stack includes iCIMS, GleSYS Internet Services, Microsoft SharePoint, WordPress, CookieScript, Microsoft 365, Twemoji and Piwik PRO Core.

What is Cantargia AB's email format?

Minus sign iconPlus sign iconCantargia AB's email format typically follows the pattern of First.Last@cantargia.com. Find more Cantargia AB email formats with LeadIQ.

How much funding has Cantargia AB raised to date?

Minus sign iconPlus sign icon As of August 2026, Cantargia AB has raised $28M in funding. The last funding round occurred on Jun 17, 2025 for $2.6M.

When was Cantargia AB founded?

Minus sign iconPlus sign iconCantargia AB was founded in 2010.
Cantargia AB logo

Cantargia AB

Biotechnology ResearchSkåne, Sweden11-50 Employees

Cantargia AB is a biotechnology research company based in Lund, Sweden, focused on developing antibody-based therapies that target IL1RAP. Its clinical portfolio includes nadunolimab in phase II for cancer and CAN10 in phase I for autoimmune and inflammatory diseases. The company employs 11-50 people and is located at 27 Scheelevägen, Lund, Skåne, 223 63, Sweden, with a website at cantargia.com. In 2025 the company underwent leadership changes, appointing Hilde Steineger as Chief Executive Officer in August, and appointing Wolfram Dempke as Chief Medical Officer in October, following the departure of Morten Lind Jensen from the CMO role in March 2025; Otsuka also announced an asset purchase related to CAN10 in 2025. Public disclosures indicate revenue in the 0 to 1 million USD range and funding of about 2.6 million USD.

Section iconCompany Overview

Phone number
+46-46-275-6****
Website
cantargia.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $28M

    Cantargia AB has raised a total of $28M of funding over 3 rounds. Their latest funding round was raised on Jun 17, 2025 in the amount of $2.6M as a Post IPO Debt.

  • <$1M

    Cantargia AB's revenue is estimated to be in the range of <$1M

Company Leadership

  • Ceo at Cantargia AB
    H. H. S.
    Ceo
    Mobile Phone
  • Chief Business Officer at Cantargia AB
    T. B.
    Chief Business Officer
    Mobile Phone
  • Chief Scientific Officer at Cantargia AB
    D. L.
    Chief Scientific Officer
    Mobile Phone
  • Chief Financial Officer at Cantargia AB
    P. R.
    Chief Financial Officer
    Mobile Phone
  • Vp Clinical Development at Cantargia AB
    L. T.
    Vp Clinical Development
    Mobile Phone

Employee Directory

  • Founder & Scientific Advisor at Cantargia AB
    T. F.
    Founder & Scientific Advisor
    Mobile Phone
  • Vp Clinical Development at Cantargia AB
    L. T.
    Vp Clinical Development
    Mobile Phone
  • Vp Biometrics at Cantargia AB
    N. L.
    Vp Biometrics
    Mobile Phone
  • Non Executive Director at Cantargia AB
    D. M.
    Non Executive Director
    Mobile Phone
  • Project Director at Cantargia AB
    A. S.
    Project Director
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.